EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Baseline and changes in inflammatory parameters for patients with EGFR ‐mutated NSCLC treated with afatinib

Zi-Ting Chang, Ping-Chih Hsu, How-Wen Ko, John Wen-Cheng Chang, Chen-Te Wu, Chen-Yang Huang, Ching-Fu Chang, Chih-Hsi Scott Kuo, Cheng-Ta Yang, Chiao-En Wu iD

Thoracic Cancer · 2025

DOI: 10.1111/1759-7714.15338 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thoracic Cancer, 2025. Verfasst von Zi-Ting Chang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, College of Medicine, Chang Gung University, Taoyuan, Taiwan. Hauptthemen laut MEDLINE: Afatinib, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Mutation. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Chang Gung Memorial Hospital, Linkou, National Science and Technology Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This study investigated the relationship between inflammatory biomarkers (lymphocyte ratio [NLR], monocyte‐to‐lymphocyte ratio [MLR], and platelet‐to‐lymphocyte ratio [PLR]) and the treatment outcomes of patients with non‐small cell lung cancer (NSCLC) treated with afatinib.

Methods

The patients with NSCLC treated with afatinib between June 2014 and February 2018 were retrospectively reviewed. Their inflammatory biomarkers and clinical outcomes (progression‐free survival [PFS] and tumor response) were explored using univariate and multivariate analyses.

Results

Among 325 patients, those with an NLR >2.18, MLR >0.19, and PLR >177.73 had significantly worse PFS than those with lower values. After adjusting for performance status, stage, and liver metastasis, the PFS was still unfavorable for a baseline NLR >2.18, MLR >0.19, or PLR > 177.73. Among 188 patients with paired inflammatory values, those whose NLR decreased by >29.5%, MLR decreased by >57.9%, and PLR increased by

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AfatinibCarcinoma, Non-Small-Cell LungLung NeoplasmsMutationInflammationHumansFemaleMaleMiddle AgedAgedRetrospective StudiesErbB ReceptorsAdultPrognosisAged, 80 and over

Stichwörter der Autor:innen

monocyte‐to‐lymphocyte rationeutrophil‐to‐lymphocyte ratioplatelet‐to‐lymphocyte ratioprognostic factorstreatment outcomes

Substanzen

AfatinibErbB ReceptorsEGFR protein, human

Autor:innen und Institutionen

  • Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
  • Division of Thoracic Oncology, Department of Thoracic Medicine, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, Taoyuan, Taiwan.
  • Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
  • Department of Medical Imaging and Intervention, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, Taoyuan, Taiwan.

ORCID-Profile: Chiao-En Wu

Förderung

  • Chang Gung Memorial Hospital, Linkou
  • National Science and Technology Council

Zitieren

APA

Chang, Z. T., Hsu, P. C., Ko, H. W., Chang, J. W., Wu, C. T., Huang, C. Y., Chang, C. F., Kuo, C. S., Yang, C. T., & Wu, C. E. (2025). Baseline and changes in inflammatory parameters for patients with EGFR ‐mutated NSCLC treated with afatinib. Thoracic Cancer. https://doi.org/10.1111/1759-7714.15338

Vancouver

Chang ZT, Hsu PC, Ko HW, Chang JW, Wu CT, Huang CY, et al. Baseline and changes in inflammatory parameters for patients with EGFR ‐mutated NSCLC treated with afatinib. Thoracic Cancer. 2025. doi:10.1111/1759-7714.15338

BibTeX
@article{Chang2025,
  author = {Chang, Zi-Ting and Hsu, Ping-Chih and Ko, How-Wen and Chang, John Wen-Cheng and Wu, Chen-Te and Huang, Chen-Yang and Chang, Ching-Fu and Kuo, Chih-Hsi Scott and Yang, Cheng-Ta and Wu, Chiao-En},
  title = {Baseline and changes in inflammatory parameters for patients with EGFR ‐mutated NSCLC treated with afatinib},
  journal = {Thoracic Cancer},
  year = {2025},
  doi = {10.1111/1759-7714.15338}
}
Kostenlos starten →